SCHEMBL4414264

SCHEMBL4414264

O=C(O)n1ccc2c(Nc3cccc(Cl)c3)ncnc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.57
KDM4E B2RXH2 2/20 0.57
MEN1 O00255 2/20 0.57
HTT P42858 2/20 0.57
KMT2A Q03164 2/20 0.57
ALDH1A1 P00352 1/20 0.57
LMNA P02545 1/20 0.57
GAA P10253 1/20 0.57
HPGD P15428 1/20 0.57
TSHR P16473 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
HSD17B10 Q99714 1/20 0.57
EGFR P00533 7/20 0.54
FADS1 O60427 2/20 0.54
LCK P06239 1/20 0.53
TTBK1 Q5TCY1 1/20 0.52
TTBK2 Q6IQ55 1/20 0.52
CCNB2 O95067 1/20 0.52
CDK1 P06493 1/20 0.52
CCNB1 P14635 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4427009 0.85 AURKA (0.58) KDM4EEGFR
SCHEMBL4421383 0.85 RAB9A (0.57) MAPTKDM4EHTTALDH1A1LMNA
SCHEMBL4415185 0.85 LMNA (0.58) MAPTKDM4EMEN1HTTKMT2A
SCHEMBL4412294 0.83 PIP4K2A (0.69) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4412666 0.83 PIP4K2A (0.48) MAPTKDM4EALDH1A1EGFRSRC
SCHEMBL4423001 0.83 ALDH1A1 (0.54) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4415661 0.82 EGFR (0.52) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4415573 0.82 PIP4K2A (0.47) MAPTKDM4EMEN1HTTKMT2A
SCHEMBL4416404 0.82 ABCG2 (0.57) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL5033064 0.82 TP53 (0.59) MAPTALDH1A1EGFRNPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7338957-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-03-04 US claimed
EP-1658290-A4 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2009-04-15 EP disclosed
US-20080108616-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-05-08 US disclosed
US-7338957-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-03-04 US disclosed
EP-1658290-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-24 EP disclosed
WO-2005039486-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108616-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS LCK, FYN, BMX MAPT 1133/4885KDM4E 3165/4885MEN1 4065/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.